Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,397JPY
11:30am IST
Change (% chg)

¥-23 (-0.36%)
Prev Close
¥6,420
Open
¥6,370
Day's High
¥6,424
Day's Low
¥6,370
Volume
590,500
Avg. Vol
1,003,850
52-wk High
¥7,148
52-wk Low
¥5,496

Select another date:

Wed, Jan 10 2018

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment

* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

BRIEF-Eisai Co to invest about $8.8 mln at Vizag plant in India - Nikkei‍​

* Eisai co to invest about $8.8 million to install manufacturing equipment at Vizag plant in India - Nikkei‍​ Source text for Eikon: Further company coverage:

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

BRIEF-Eisai Co signs agreement with Grupo Biotoscana granting GBT exclusive licensing rights

* Eisai Co - signed agreement with Grupo Biotoscana granting GBT exclusive licensing rights

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures

BRIEF-Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

* Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

Select another date: